Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNB-102
- Development stage
- Preclinical
- Lead developer
- De Novo Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral
01
Overview
DNB-102 is a preclinical-stage therapeutic candidate being developed by De Novo Biotherapeutics for the treatment of multiple myeloma. It utilizes an mRNA-based platform to encode a bispecific antibody designed as an NK cell engager. While the specific tumor-associated antigen target remains undisclosed, the modality aims to recruit and activate natural killer (NK) cells to selectively eliminate malignant plasma cells. By delivering the genetic instructions for the bispecific antibody via mRNA, the approach potentially offers advantages in production and sustained in vivo expression compared to traditional protein-based bispecific antibodies.
Beyond the preview
Go deeper on DNB-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNB-102.